Cardioprotective Effects of Coenzyme Q10 Supplementation on Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Q4 Pharmacology, Toxicology and Pharmaceutics
A. Yazdi, Kimia Shirmohammadi, E. Parvaneh, S. K. Hosseini, A. Ranjbar, M. Mehrpooya
{"title":"Cardioprotective Effects of Coenzyme Q10 Supplementation on Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","authors":"A. Yazdi, Kimia Shirmohammadi, E. Parvaneh, S. K. Hosseini, A. Ranjbar, M. Mehrpooya","doi":"10.34172/ps.2023.8","DOIUrl":null,"url":null,"abstract":"Background: We assessed the potential efficacy of Coenzyme Q10 (CoQ10) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods: Seventy STEMI patients who presented ≤12 hours after the onset of symptoms and were scheduled for PPCI were randomly assigned to the standard treatments plus CoQ10 or placebo. In the intervention group, CoQ10, as an oral capsule at a dose of 400 mg, was loaded immediately before PPCI and continued at 200 mg twice daily for 28 days. The control group received a matching placebo, similarly. The study endpoints were the proportion of patients with complete myocardial reperfusion, defined as thrombolysis in myocardial infarction (TIMI) flow and myocardial blush grade (MBG) 3 at the end of PPCI, the proportion of patients with complete ST-segment elevation resolution (≥70%) assessed 60 minutes after PPCI, the plasma levels of creatine kinase myocardial band isoenzyme (CK-MB) and troponin I (TnI) at 12, 24, 48, and 72 hours after PPCI, and left ventricular ejection fraction (LVEF) at day 28. Results: The study groups were comparable regarding baseline clinical and procedural characteristics. The proportion of patients with TIMI flow grade 3, MBG 3, and complete ST resolution after completion of PPCI was similar between the groups. Whereas at all-time points after PPCI (12, 24, 48, and 72 hours), the plasma levels of CK-MB and TnI were significantly lower in the CoQ10 group than in the control group. Further, at day 28, CoQ10-treated patients exhibited better LVEF than placebo-treated patients, and the proportion of patients with LVEF less than 50% was lower in the intervention group than in the control group. Conclusion: Our study provided evidence that CoQ10 supplementation might reduce myocardial ischemia-reperfusion injury after PPCI and help to preserve left ventricular function. However, further studies are required to validate these results.","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"118 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infarma Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/ps.2023.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Background: We assessed the potential efficacy of Coenzyme Q10 (CoQ10) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods: Seventy STEMI patients who presented ≤12 hours after the onset of symptoms and were scheduled for PPCI were randomly assigned to the standard treatments plus CoQ10 or placebo. In the intervention group, CoQ10, as an oral capsule at a dose of 400 mg, was loaded immediately before PPCI and continued at 200 mg twice daily for 28 days. The control group received a matching placebo, similarly. The study endpoints were the proportion of patients with complete myocardial reperfusion, defined as thrombolysis in myocardial infarction (TIMI) flow and myocardial blush grade (MBG) 3 at the end of PPCI, the proportion of patients with complete ST-segment elevation resolution (≥70%) assessed 60 minutes after PPCI, the plasma levels of creatine kinase myocardial band isoenzyme (CK-MB) and troponin I (TnI) at 12, 24, 48, and 72 hours after PPCI, and left ventricular ejection fraction (LVEF) at day 28. Results: The study groups were comparable regarding baseline clinical and procedural characteristics. The proportion of patients with TIMI flow grade 3, MBG 3, and complete ST resolution after completion of PPCI was similar between the groups. Whereas at all-time points after PPCI (12, 24, 48, and 72 hours), the plasma levels of CK-MB and TnI were significantly lower in the CoQ10 group than in the control group. Further, at day 28, CoQ10-treated patients exhibited better LVEF than placebo-treated patients, and the proportion of patients with LVEF less than 50% was lower in the intervention group than in the control group. Conclusion: Our study provided evidence that CoQ10 supplementation might reduce myocardial ischemia-reperfusion injury after PPCI and help to preserve left ventricular function. However, further studies are required to validate these results.
补充辅酶Q10对st段抬高型心肌梗死患者经皮冠状动脉介入治疗的心脏保护作用
背景:我们评估了辅酶Q10 (CoQ10)在st段抬高型心肌梗死(STEMI)患者接受原发性经皮冠状动脉介入治疗(PPCI)的潜在疗效。方法:70例在症状出现≤12小时后出现并计划进行PPCI的STEMI患者随机分配到标准治疗加辅酶q10或安慰剂组。在干预组中,辅酶q10作为口服胶囊,剂量为400 mg,在PPCI前立即加载,并继续每天两次,剂量为200 mg,持续28天。对照组也接受了相同的安慰剂。研究终点是PPCI结束时心肌再灌注完全患者的比例,定义为心肌梗死(TIMI)血流溶栓和心肌红度(MBG) 3级,PPCI后60分钟评估的st段完全抬高分辨率(≥70%)的患者比例,PPCI后12、24、48和72小时的血浆肌酸激酶心肌带同型酶(CK-MB)和肌钙蛋白I (TnI)水平,第28天左心室射血分数(LVEF)。结果:两个研究组在基线临床和程序特征方面具有可比性。两组患者在PPCI完成后TIMI血流3级、MBG 3级和ST完全消退的比例相似。而在PPCI后的各个时间点(12,24,48和72小时),CoQ10组的血浆CK-MB和TnI水平明显低于对照组。此外,在第28天,coq10治疗的患者表现出比安慰剂治疗的患者更好的LVEF,并且干预组LVEF低于50%的患者比例低于对照组。结论:本研究证明补充辅酶q10可减轻PPCI后心肌缺血再灌注损伤,有助于保持左心室功能。然而,需要进一步的研究来验证这些结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
17
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信